Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling

OBJECTIVE: In patients with severe or refractory juvenile dermatomyositis (DM), second‐line treatments may be required. Cyclophosphamide (CYC) is used to treat some connective tissue diseases, but evidence of its efficacy in juvenile DM is limited. This study was undertaken to describe clinical impr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Rheumatol
Main Authors: Deakin, Claire T., Campanilho‐Marques, Raquel, Simou, Stefania, Moraitis, Elena, Wedderburn, Lucy R., Pullenayegum, Eleanor, Pilkington, Clarissa A.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Pediatric Rheumatology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5947636/
https://ncbi.nlm.nih.gov/pubmed/29342499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40418
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados